Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study

BACKGROUND: Multiple sclerosis (MS) currently requires long-term treatment with disease-modifying drugs, administered parenterally up to once daily. The need for regular self-injection can be a barrier to treatment for many patients. Autoinjectors can help patients overcome problems or concerns with...

Descripción completa

Detalles Bibliográficos
Autores principales: Devonshire, Virginia, Arbizu, Txomin, Borre, Björn, Lang, Michael, Lugaresi, Alessandra, Singer, Barry, Verdun di Cantogno, Elisabetta, Cornelisse, Peter
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2877661/
https://www.ncbi.nlm.nih.gov/pubmed/20433746
http://dx.doi.org/10.1186/1471-2377-10-28

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2877661/
https://www.ncbi.nlm.nih.gov/pubmed/20433746
http://dx.doi.org/10.1186/1471-2377-10-28

Ejemplares similares